Predictive molecular profiling in blood of healthy vasospastic individuals: Clue to targeted prevention as personalised medicine to effective costs

EPMA Journal

Volumn 1, Issue 2, 2010, Pages 263-272

  Yeghiazaryan, Kristina ^a,b   Flammer, Josef ^b,c   Golubnitschaja, Olga ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b Preventive and Personalised Medicine   (United States)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Blood biomarkers; Personalised medicine; Predictive diagnostics; Predisposition in healthy individuals; Targeted prevention; Vascular deregulation

Indexed keywords

ENDOTHELIN 1; INTERCELLULAR ADHESION MOLECULE 1; METALLOPROTEINASE; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y RECEPTOR 7; SODIUM CALCIUM EXCHANGE PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; CELL DEATH; DNA DAMAGE; DNA REPAIR; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; EYE BLOOD FLOW; GENE EXPRESSION PROFILING; GLAUCOMA; HEALTH CARE COST; HUMAN; LEUKOCYTE; MICROSCOPY; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PERSONALIZED MEDICINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREVALENCE; PREVENTION STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RACISM; RETINA GANGLION CELL; REVIEW; SEX DIFFERENCE; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNINDEXED SEQUENCE; UPREGULATION; VASOSPASM; VASOSPASTIC SYNDROME;

EID: 77957596581     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0032-3     Document Type: Review

References (39)

1. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res. 2001; 20: 319-49.
2. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol. 1999; 33: 1442-52.
3. Flammer J. Glaucoma. A guide for patients. An introduction for care providers. A quick reference. 3rd revised edition. Bern, Hogrefe & Huber Publishers, 2006.
4. Teuchner B, Orgül S, Ulmer H, et al. Reduced thirst in patients with a vasospastic syndrome. Acta Ophthalmol Scand. 2004; 82: 738-40.
5. Wunderlich K, Zimmerman C, Gutmann H, et al. Vasospastic persons exhibit differential expression of ABC-transport proteins. Mol Vis. 2003; 9: 756-61.
6. Flammer J. Innovative glaucoma therapy. Ophthalmologe. 2001; 98: 923-4.
7. Finsterer J. Mitochondriopathies. Eur J Neurol. 2004; 11: 163-86.
8. Flammer J, Guthauser U, Mahler M. Do ocular vasospasms help cause low-tension glaucoma? Doc Ophthalmol Proc Ser. 1987; 49: 397-9.
9. Guthauser U, Flammer J, Mahler F. The relationship between digital and ocular vasospasm. Graefes Arch Clin Exp Ophthalmol. 1988; 226: 224-6.
10. Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002; 21: 359-93.
11. Golubnitschaja O, Wunderlich K, Decker C, et al. Molecular imaging of perfusion disturbances in glaucoma. Amino Acids. 2002; 23: 293-9.
12. Golubnitschaja O, Yeghiazaryan K, Liu R, et al. Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J Glaucoma. 2004; 13: 66-72.
13. Golubnitschaja-Labudova O, Liu R, Decker C, et al. Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr Eye Res. 2000; 21: 867-76.
14. Wunderlich K, Golubnitschaja O, Pache M, et al. Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: an observational pilot study. Mol Vis. 2002; 8: 431-5.
15. Yeghiazaryan K, Flammer J, Orgül S, et al. Vasospastic individuals demonstrate significant similarity to glaucoma patients as revealed by gene expression profiling in circulating leukocytes. Mol Vis. 2009; 15: 2339-48.
16. Golubnitschaja O, Flammer J. What are the biomarkers for Glaucoma? Surv Ophthalmol. 2007; 52: S155-61.
17. Golubnitschaja O, Yeghiazaryan K, Flammer J. Key molecular pathways affected by glaucoma pathology: Is predictive diagnosis possible? The EPMA Journal. 2010; doi: 10. 1007/s13167-010-0031-4.
18. Golubnitschaja O, Yeghiazaryan K, Orgül S, et al. What are the biomarkers for Glaucoma? In: Golubnitshaja O, editor. Predictive diagnostics and personalized treatment: dream or reality. New York: Nova Science Publishers; 2009. p. 375-96.
19. Moenkemann H, Flammer J, Wunderlich K, et al. Increased DNA breaks and up-regulation of both G(1) and G(2) checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in circulating leukocytes of glaucoma patients and vasospastic individuals. Amino Acids. 2005; 28: 199-205.
20. Golubnitschaja O, Moenkemann H, Kim K, et al. DNA damage and expression of checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in taurine-deficient cardiomyocytes. Biochem Pharmacol. 2003; 66: 511-7.
21. Migliore L, Fontana I, Colognato R, et al. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging. 2005; 26: 587-95.
22. Golubnitschaja O, Yeghiazaryan K, Wunderlich K, et al. Disease proteomics reveals altered basic gene expression regulation in leukocytes of glaucoma patients. Proteomics Clin Appl. 2007; 1: 1316-23.
23. Kannan S. Amplification of extracellular nucleotide-induced leukocyte(s) degranulation by contingent autocrine and paracrine mode of leukotriene-mediated chemokine receptor activation. Med Hypotheses. 2002; 59: 261-5.
24. Di Gennaro A, Carnini C, Buccellati C, et al. Cysteinylleukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes. FASEB J. 2004; 18: 842-4.
25. Rosnowska M, Cendrowski W, Sobczyk W. Leukotrienes B4 and C4 in cerebrospinal of patients with multiple sclerosis. Pol Merkur Lekarski. 1997; 2: 254-5.
26. Akbar GK, Dasari VR, Webb TE, et al. Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells. J Biol Chem. 1996; 271: 18363-7.
27. Dasari VR, Jin J, Kunapuli SP. Distribution of leukotriene B4 receptors in human hematopoietic cells. Immunopharmacology. 2000; 48: 157-63.
28. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids. 2003; 69: 123-34.
29. Pintor J, Peral A, Peláez T, et al. Presence of diadenosine polyphosphates in the aqueous humor: their effect on intraocular pressure. J Pharmacol Exp Ther. 2003; 304: 342-8.
30. Akopov SE, Sercombe R, Seylaz J. Actions of plateletactivating factor on isolated rabbit basilar artery: modulation by activated polymorphonuclear leukocytes. J Vasc Res. 1995; 32: 49-57.
31. Akopov S, Sercombe R, Seylaz J. Cerebrovascular reactivity: role of endothelium/platelet/leukocyte interactions. Cerebrovasc Brain Metab Rev. 1996; 8: 11-94.
32. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991; 67: 1033-6.
33. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab. 1999; 19: 819-34.
34. Chen H, Chopp M, Zhang RL, et al. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol. 1994; 35: 458-63.
35. Connolly Jr ES, Winfree CJ, Springer TA, et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest. 1996; 97: 209-16.
36. 2+ regulation and blood pressure: the gender effect. Hypertension. 1998; 32: 869-74.
37. Marrelli SP. Mechanisms of endothelial P2Y(1)- and P2Y(2)-mediated vasodilatation involve differential [Ca2+]I responses. Am J Physiol Heart Circ Physiol. 2001; 281: H1759-66.
38. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43: 109-42.
39. Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system. Biochem J. 1998; 336: 513-23.